Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04517747
Title Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction (RE-ExPEL)
Recruitment Active, not recruiting
Gender both
Phase Phase 0
Variant Requirements No
Sponsors Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Indications

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Ramucirumab + Trifluridine-tipiracil hydrochloride

Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.